CANADA LIFE ASSURANCE Co Acquires 8,290 Shares of Xencor, Inc. (NASDAQ:XNCR)

CANADA LIFE ASSURANCE Co grew its holdings in Xencor, Inc. (NASDAQ:XNCR) by 11.0% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 83,535 shares of the biopharmaceutical company’s stock after acquiring an additional 8,290 shares during the period. CANADA LIFE ASSURANCE Co owned 0.12% of Xencor worth $1,918,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Sterling Capital Management LLC grew its position in Xencor by 732.4% in the fourth quarter. Sterling Capital Management LLC now owns 1,182 shares of the biopharmaceutical company’s stock worth $27,000 after acquiring an additional 1,040 shares in the last quarter. GAMMA Investing LLC grew its position in Xencor by 31.0% in the fourth quarter. GAMMA Investing LLC now owns 2,147 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 508 shares in the last quarter. KBC Group NV boosted its holdings in shares of Xencor by 26.0% during the 4th quarter. KBC Group NV now owns 3,936 shares of the biopharmaceutical company’s stock worth $90,000 after buying an additional 813 shares during the period. PNC Financial Services Group Inc. boosted its holdings in shares of Xencor by 49.4% during the 4th quarter. PNC Financial Services Group Inc. now owns 4,041 shares of the biopharmaceutical company’s stock worth $93,000 after buying an additional 1,337 shares during the period. Finally, Summit Investment Advisors Inc. boosted its holdings in shares of Xencor by 22.2% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,045 shares of the biopharmaceutical company’s stock worth $162,000 after buying an additional 1,282 shares during the period.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on XNCR. William Blair began coverage on shares of Xencor in a report on Monday, April 21st. They set an “outperform” rating for the company. StockNews.com downgraded shares of Xencor from a “hold” rating to a “sell” rating in a report on Friday, March 14th. Finally, Wells Fargo & Company decreased their price objective on shares of Xencor from $37.00 to $33.00 and set an “overweight” rating for the company in a report on Friday, February 28th. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $33.86.

Xencor Stock Performance

NASDAQ XNCR opened at $10.51 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.23 and a quick ratio of 6.23. The firm has a market capitalization of $740.56 million, a price-to-earnings ratio of -3.28 and a beta of 0.90. The company’s fifty day moving average is $11.77 and its two-hundred day moving average is $18.41. Xencor, Inc. has a 52-week low of $7.16 and a 52-week high of $27.24.

Xencor (NASDAQ:XNCR) last released its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.62) EPS for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.19. The company had revenue of $52.79 million during the quarter, compared to the consensus estimate of $17.14 million. Xencor had a negative net margin of 232.77% and a negative return on equity of 30.92%. Equities research analysts forecast that Xencor, Inc. will post -3.68 EPS for the current year.

About Xencor

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.